RxDoctor Payments Data

Paul Hixon, MD

Family Medicine · Shamokin, PANPI 1710340112

Payments from drug & device makers

$740in general payments, 2019–2025

Across 36 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$162
  • AstraZeneca$123
  • Exact Sciences$82
  • Novo Nordisk$68
  • Verona Pharma, Inc.$47
  • Phathom Pharmaceuticals, Inc.$46
  • plus $213 from 8 others

What the payments were for

  • Food & beverage$740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$740 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,463
Medicare patients
356
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$53,753
JardianceEmpagliflozin87$52,541
OzempicSemaglutide48$49,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,900
XareltoRivaroxaban15$18,145
JanuviaSitagliptin Phosphate13$14,847
Breo ElliptaFluticasone/Vilanterol14$7,741
MyrbetriqMirabegron25$6,723
Potassium Chloride109$6,319
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$6,191
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,173
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,078
Atorvastatin Calcium386$4,733
Incruse ElliptaUmeclidinium Bromide13$3,914
Omeprazole276$3,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$53,75399 claims
Novo NordiskOzempic$68$49,19148 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$162$35,55561 claims
MerckJanuvia$19$14,84713 claims
AbbVieSynthroid$32$1,06220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Shamokin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →